Endoluminal Suturing Devices Market by Product Type (Disposable Systems, Reusable Systems), Technology (Automated, Manual), Application, End User, Distribution Channel - Global Forecast 2025-2032
Description
The Endoluminal Suturing Devices Market was valued at USD 48.44 billion in 2024 and is projected to grow to USD 54.73 billion in 2025, with a CAGR of 13.23%, reaching USD 130.90 billion by 2032.
A concise and authoritative introduction to endoluminal suturing devices that maps clinical utility, technological evolution, and stakeholder implications for healthcare delivery
Endoluminal suturing devices have emerged as a pivotal class of tools that extend the capabilities of endoscopic therapy beyond diagnostic procedures into durable therapeutic interventions. These devices enable clinicians to perform a range of interventions within the lumen of the gastrointestinal tract and other hollow organs, replacing or complementing traditional open and laparoscopic approaches. Advances in device ergonomics, suture materials, and delivery mechanisms have improved procedural reliability and broadened the range of clinical indications where endoluminal suturing is considered a practical option.
Clinicians and healthcare leaders view these technologies not only as technical innovations but as enablers of value-based care. Shorter hospital stays, reduced postoperative pain, and faster recovery profiles are commonly cited clinical benefits that align with institutional objectives to optimize patient throughput and reduce resource intensity. At the same time, developers face a complex landscape of regulatory requirements, device interoperability challenges, and the need to demonstrate reproducible outcomes across varied practice settings. Consequently, the ecosystem around endoluminal suturing includes device manufacturers, end users such as ambulatory surgical centers and hospitals, distribution partners, and clinical researchers working to integrate these devices into standard treatment pathways.
Transformative clinical, technological, and commercial shifts that are redefining adoption dynamics and competitive positioning within the endoluminal suturing device landscape
Shifts in the clinical and commercial landscape for endoluminal suturing devices are accelerating as multiple enabling technologies converge. Robotics-inspired articulation, improved imaging integration, and more intuitive user interfaces are reshaping how endoscopists approach complex suturing tasks. Procedural workflows that once required advanced laparoscopic skill sets can now be performed endoluminally by gastroenterologists leveraging purpose-built suturing platforms, changing referral patterns and expanding the pool of potential adopters.
Regulatory and reimbursement environments are evolving to reflect the growing evidence base around endoluminal interventions. As clinical data accumulates on outcomes for applications such as endoscopic sleeve gastroplasty and endoscopic submucosal dissection, payers and health systems are increasingly focused on pathway optimization and credentialing frameworks. Concurrently, supply chain dynamics are shifting toward hybrid commercial models that combine direct engagement with strategic customers and partnerships with specialized distributors. This transition is prompting manufacturers to refine product portfolios across disposable and reusable systems, and to invest in physician training and postmarket surveillance to support long-term clinical adoption.
Assessment of 2025 tariff developments and their multifaceted implications for sourcing strategies, pricing, and supply chain resilience across endoluminal suturing device manufacturers
Tariff policy developments in 2025 have introduced additional considerations for companies operating in the global supply chain for endoluminal suturing devices. Increased duties on certain imported components and finished devices have the potential to influence sourcing decisions, production footprints, and pricing strategies. Manufacturers that rely on multinational supplier networks may evaluate alternatives such as nearshoring, strategic inventory buffering, or renegotiation of supplier agreements to mitigate margin pressure.
These adjustments are occurring alongside persistent supply chain sensitivities that surfaced during recent global disruptions, prompting stakeholders to re-examine vendor diversification and contract structures. For device makers, the imperative is to balance cost containment with the need to preserve product quality and regulatory compliance. Health systems and procurement organizations, meanwhile, are likely to weigh the total cost of care implications of any price changes against clinical outcomes and throughput benefits. In practice, this dynamic will favor companies with flexible manufacturing models, established in-region capabilities, and the ability to clearly communicate value propositions that offset any incremental tariff-induced cost impacts.
In-depth segmentation insights that align product design, clinical applications, end-user profiles, and distribution models to strategic commercialization choices for device makers
Segmentation analysis reveals where clinical needs, purchasing behavior, and technological preferences intersect to shape product strategy. Based on Product Type, market is studied across Disposable Systems and Reusable Systems, which compels manufacturers to define aftermarket economics, sterilization protocols, and service models that reflect end-user priorities. Decision cycles differ markedly between disposable-centric offerings that prioritize single-use convenience and reusable platforms that demand durable designs and predictable lifecycle costs.
Based on Technology, market is studied across Automated and Manual, creating distinct value propositions for procedural efficiency and user training. Automated systems emphasize consistency and reduced operator variability, while manual systems appeal to practices that prioritize tactile control and lower capital outlay. Based on Application, market is studied across Endoscopic Mucosal Resection, Endoscopic Sleeve Gastroplasty, Endoscopic Submucosal Dissection, and Peroral Endoscopic Myotomy, each presenting unique procedural requirements, suture patterns, and evidence thresholds necessary to drive adoption. Based on End User, market is studied across Ambulatory Surgical Centers, Hospitals, and Specialty Clinics. The Hospitals is further studied across Academic Hospitals and Community Hospitals, reflecting divergent purchasing behaviors, clinical expertise concentrations, and throughput expectations that influence product choice and training investments. Based on Distribution Channel, market is studied across Direct Sales and Distributors. The Distributors is further studied across Value Added Resellers and Wholesalers, signaling that channel strategy must reconcile the need for clinical education and service support with broad geographic reach and cost-efficiency.
Collectively, these segmentation dimensions illustrate why a one-size-fits-all commercial approach is unlikely to succeed. Strategic segmentation enables prioritization of development investment, aligning device features and support models to the operational realities of ambulatory centers, teaching hospitals, and specialty clinics. Furthermore, channel selection and technology mix should be considered in tandem to optimize adoption curves and post-sale support costs.
Regional insights into how adoption drivers, regulatory contexts, and healthcare delivery models across the Americas, Europe, Middle East & Africa, and Asia-Pacific influence strategic entry and scale-up
Regional dynamics introduce important variance in clinical practice patterns, regulatory pathways, and procurement norms that influence adoption timelines for endoluminal suturing technologies. In the Americas, payer structures and a strong emphasis on value-based care are driving institutions to evaluate interventions that reduce length of stay and readmission risk, while academic centers continue to lead in technique development and evidence generation. In Europe, Middle East & Africa, regulatory harmonization initiatives and heterogeneous healthcare delivery models create both opportunities and complexity for market entrants, with select national health systems driving early adoption where reimbursement and clinical champions align. In the Asia-Pacific region, diverse patient populations and a high throughput environment in many tertiary centers create favourable conditions for procedural innovation, though local regulatory requirements and cost sensitivity necessitate thoughtful market entry strategies.
Geographic footprint decisions should account for training infrastructure, the availability of procedural champions, and regional supply chain considerations. Manufacturers seeking to scale internationally will benefit from partnerships that bridge clinical education with local regulatory expertise, enabling credible evidence translation across distinct healthcare ecosystems. As a result, regional prioritization should be informed by a clear view of where clinical need, reimbursement readiness, and distribution capability converge to support sustainable adoption.
Critical company-level insights that reveal how product differentiation, clinical partnerships, and operational capabilities determine competitive positioning in the endoluminal suturing ecosystem
Competitive dynamics in the endoluminal suturing space are influenced by the interplay between established medical device firms and agile innovators. Companies that combine robust clinical support programs, comprehensive training curricula, and postmarket data collection capabilities tend to achieve deeper penetration in hospital systems and specialist practices. Differentiation is often achieved through a combination of device ergonomics, the versatility of suture patterns supported, and the integration of imaging or navigation aids that simplify complex endoluminal tasks.
Partnerships with clinical societies and key opinion leaders are critical for accelerating procedural adoption and establishing real-world evidence. Additionally, organizations with demonstrated manufacturing quality, strong regulatory track records, and scalable distribution networks can more effectively respond to procurement cycles in both academic teaching hospitals and community hospital systems. For newer entrants, focusing on niche applications where procedural benefit is clear can create beachheads that validate technology and support subsequent expansion into broader clinical indications.
Actionable recommendations for industry leaders to synchronize product architecture, clinical evidence, and supply chain strategies to accelerate durable adoption and commercial resilience
Leaders in this sector should prioritize an aligned strategy that connects product design with clinical training, reimbursement engagement, and supply chain resilience. Investing in modular platforms that accommodate both disposable and reusable configurations can create flexible value propositions tailored to distinct end-user needs. Simultaneously, developers should accelerate evidence generation for priority applications such as endoscopic sleeve gastroplasty and endoscopic submucosal dissection to strengthen payer conversations and institutional adoption pathways.
Operationally, diversifying manufacturing and leveraging regional production capabilities will mitigate tariff and logistics exposure while improving responsiveness to local demand. Commercial teams must create hybrid go-to-market models that blend direct clinical engagement with selected distributor partnerships able to deliver service and regional coverage. Finally, embedding robust postmarket data capture into device ecosystems will provide the empirical foundation needed to refine training programs, optimize protocols, and demonstrate long-term clinical and economic value to health systems and payers.
Transparent research methodology detailing primary clinical engagement and secondary technical synthesis to ensure validated and actionable insights for stakeholders
The research that underpins these insights relied on a structured methodology combining primary stakeholder engagement and secondary technical synthesis. Primary inputs were gathered through interviews with practicing endoscopists, surgical gastroenterologists, procurement leaders, and distribution partners to capture firsthand perspectives on device usability, training requirements, and purchasing considerations. These qualitative discussions were designed to surface nuanced operational realities that influence adoption in ambulatory surgical centers, academic hospitals, and community hospitals.
Secondary analysis incorporated peer-reviewed clinical literature, regulatory filings, procedure coding guidance, and publicly available technical specifications to validate device capabilities and clinical applicability. Cross-validation of findings ensured that procedural applications, technology distinctions between automated and manual systems, and distinctions between disposable systems and reusable systems were accurately represented. Wherever possible, triangulation between clinician input, published clinical evidence, and device documentation was used to strengthen the reliability of conclusions and recommendations.
Concluding perspective that synthesizes clinical promise, commercial imperatives, and strategic prerequisites for sustainable adoption of endoluminal suturing technologies
In conclusion, endoluminal suturing devices occupy a strategic intersection of clinical innovation and health system optimization. Technological refinements and expanding procedural applications are creating opportunities to shift certain interventions from the operating room to lower-acuity settings, but successful adoption requires more than a capable device. It demands credible evidence, targeted training programs, aligned reimbursement strategies, and resilient supply chain models that together reduce adoption friction and sustain long-term clinical value.
Stakeholders who adopt a segmented approach to product development and commercialization - one that acknowledges differences across product type, technology, application, end user, and distribution channel - will be better positioned to convert clinical potential into routine practice. Regional nuances further underscore the importance of locally tailored strategies. Ultimately, the path to widespread adoption is iterative: continuous clinical engagement, data-driven refinement, and strategic partnerships will determine which solutions deliver scalable benefits to patients and healthcare systems alike.
Please Note: PDF & Excel + Online Access - 1 Year
A concise and authoritative introduction to endoluminal suturing devices that maps clinical utility, technological evolution, and stakeholder implications for healthcare delivery
Endoluminal suturing devices have emerged as a pivotal class of tools that extend the capabilities of endoscopic therapy beyond diagnostic procedures into durable therapeutic interventions. These devices enable clinicians to perform a range of interventions within the lumen of the gastrointestinal tract and other hollow organs, replacing or complementing traditional open and laparoscopic approaches. Advances in device ergonomics, suture materials, and delivery mechanisms have improved procedural reliability and broadened the range of clinical indications where endoluminal suturing is considered a practical option.
Clinicians and healthcare leaders view these technologies not only as technical innovations but as enablers of value-based care. Shorter hospital stays, reduced postoperative pain, and faster recovery profiles are commonly cited clinical benefits that align with institutional objectives to optimize patient throughput and reduce resource intensity. At the same time, developers face a complex landscape of regulatory requirements, device interoperability challenges, and the need to demonstrate reproducible outcomes across varied practice settings. Consequently, the ecosystem around endoluminal suturing includes device manufacturers, end users such as ambulatory surgical centers and hospitals, distribution partners, and clinical researchers working to integrate these devices into standard treatment pathways.
Transformative clinical, technological, and commercial shifts that are redefining adoption dynamics and competitive positioning within the endoluminal suturing device landscape
Shifts in the clinical and commercial landscape for endoluminal suturing devices are accelerating as multiple enabling technologies converge. Robotics-inspired articulation, improved imaging integration, and more intuitive user interfaces are reshaping how endoscopists approach complex suturing tasks. Procedural workflows that once required advanced laparoscopic skill sets can now be performed endoluminally by gastroenterologists leveraging purpose-built suturing platforms, changing referral patterns and expanding the pool of potential adopters.
Regulatory and reimbursement environments are evolving to reflect the growing evidence base around endoluminal interventions. As clinical data accumulates on outcomes for applications such as endoscopic sleeve gastroplasty and endoscopic submucosal dissection, payers and health systems are increasingly focused on pathway optimization and credentialing frameworks. Concurrently, supply chain dynamics are shifting toward hybrid commercial models that combine direct engagement with strategic customers and partnerships with specialized distributors. This transition is prompting manufacturers to refine product portfolios across disposable and reusable systems, and to invest in physician training and postmarket surveillance to support long-term clinical adoption.
Assessment of 2025 tariff developments and their multifaceted implications for sourcing strategies, pricing, and supply chain resilience across endoluminal suturing device manufacturers
Tariff policy developments in 2025 have introduced additional considerations for companies operating in the global supply chain for endoluminal suturing devices. Increased duties on certain imported components and finished devices have the potential to influence sourcing decisions, production footprints, and pricing strategies. Manufacturers that rely on multinational supplier networks may evaluate alternatives such as nearshoring, strategic inventory buffering, or renegotiation of supplier agreements to mitigate margin pressure.
These adjustments are occurring alongside persistent supply chain sensitivities that surfaced during recent global disruptions, prompting stakeholders to re-examine vendor diversification and contract structures. For device makers, the imperative is to balance cost containment with the need to preserve product quality and regulatory compliance. Health systems and procurement organizations, meanwhile, are likely to weigh the total cost of care implications of any price changes against clinical outcomes and throughput benefits. In practice, this dynamic will favor companies with flexible manufacturing models, established in-region capabilities, and the ability to clearly communicate value propositions that offset any incremental tariff-induced cost impacts.
In-depth segmentation insights that align product design, clinical applications, end-user profiles, and distribution models to strategic commercialization choices for device makers
Segmentation analysis reveals where clinical needs, purchasing behavior, and technological preferences intersect to shape product strategy. Based on Product Type, market is studied across Disposable Systems and Reusable Systems, which compels manufacturers to define aftermarket economics, sterilization protocols, and service models that reflect end-user priorities. Decision cycles differ markedly between disposable-centric offerings that prioritize single-use convenience and reusable platforms that demand durable designs and predictable lifecycle costs.
Based on Technology, market is studied across Automated and Manual, creating distinct value propositions for procedural efficiency and user training. Automated systems emphasize consistency and reduced operator variability, while manual systems appeal to practices that prioritize tactile control and lower capital outlay. Based on Application, market is studied across Endoscopic Mucosal Resection, Endoscopic Sleeve Gastroplasty, Endoscopic Submucosal Dissection, and Peroral Endoscopic Myotomy, each presenting unique procedural requirements, suture patterns, and evidence thresholds necessary to drive adoption. Based on End User, market is studied across Ambulatory Surgical Centers, Hospitals, and Specialty Clinics. The Hospitals is further studied across Academic Hospitals and Community Hospitals, reflecting divergent purchasing behaviors, clinical expertise concentrations, and throughput expectations that influence product choice and training investments. Based on Distribution Channel, market is studied across Direct Sales and Distributors. The Distributors is further studied across Value Added Resellers and Wholesalers, signaling that channel strategy must reconcile the need for clinical education and service support with broad geographic reach and cost-efficiency.
Collectively, these segmentation dimensions illustrate why a one-size-fits-all commercial approach is unlikely to succeed. Strategic segmentation enables prioritization of development investment, aligning device features and support models to the operational realities of ambulatory centers, teaching hospitals, and specialty clinics. Furthermore, channel selection and technology mix should be considered in tandem to optimize adoption curves and post-sale support costs.
Regional insights into how adoption drivers, regulatory contexts, and healthcare delivery models across the Americas, Europe, Middle East & Africa, and Asia-Pacific influence strategic entry and scale-up
Regional dynamics introduce important variance in clinical practice patterns, regulatory pathways, and procurement norms that influence adoption timelines for endoluminal suturing technologies. In the Americas, payer structures and a strong emphasis on value-based care are driving institutions to evaluate interventions that reduce length of stay and readmission risk, while academic centers continue to lead in technique development and evidence generation. In Europe, Middle East & Africa, regulatory harmonization initiatives and heterogeneous healthcare delivery models create both opportunities and complexity for market entrants, with select national health systems driving early adoption where reimbursement and clinical champions align. In the Asia-Pacific region, diverse patient populations and a high throughput environment in many tertiary centers create favourable conditions for procedural innovation, though local regulatory requirements and cost sensitivity necessitate thoughtful market entry strategies.
Geographic footprint decisions should account for training infrastructure, the availability of procedural champions, and regional supply chain considerations. Manufacturers seeking to scale internationally will benefit from partnerships that bridge clinical education with local regulatory expertise, enabling credible evidence translation across distinct healthcare ecosystems. As a result, regional prioritization should be informed by a clear view of where clinical need, reimbursement readiness, and distribution capability converge to support sustainable adoption.
Critical company-level insights that reveal how product differentiation, clinical partnerships, and operational capabilities determine competitive positioning in the endoluminal suturing ecosystem
Competitive dynamics in the endoluminal suturing space are influenced by the interplay between established medical device firms and agile innovators. Companies that combine robust clinical support programs, comprehensive training curricula, and postmarket data collection capabilities tend to achieve deeper penetration in hospital systems and specialist practices. Differentiation is often achieved through a combination of device ergonomics, the versatility of suture patterns supported, and the integration of imaging or navigation aids that simplify complex endoluminal tasks.
Partnerships with clinical societies and key opinion leaders are critical for accelerating procedural adoption and establishing real-world evidence. Additionally, organizations with demonstrated manufacturing quality, strong regulatory track records, and scalable distribution networks can more effectively respond to procurement cycles in both academic teaching hospitals and community hospital systems. For newer entrants, focusing on niche applications where procedural benefit is clear can create beachheads that validate technology and support subsequent expansion into broader clinical indications.
Actionable recommendations for industry leaders to synchronize product architecture, clinical evidence, and supply chain strategies to accelerate durable adoption and commercial resilience
Leaders in this sector should prioritize an aligned strategy that connects product design with clinical training, reimbursement engagement, and supply chain resilience. Investing in modular platforms that accommodate both disposable and reusable configurations can create flexible value propositions tailored to distinct end-user needs. Simultaneously, developers should accelerate evidence generation for priority applications such as endoscopic sleeve gastroplasty and endoscopic submucosal dissection to strengthen payer conversations and institutional adoption pathways.
Operationally, diversifying manufacturing and leveraging regional production capabilities will mitigate tariff and logistics exposure while improving responsiveness to local demand. Commercial teams must create hybrid go-to-market models that blend direct clinical engagement with selected distributor partnerships able to deliver service and regional coverage. Finally, embedding robust postmarket data capture into device ecosystems will provide the empirical foundation needed to refine training programs, optimize protocols, and demonstrate long-term clinical and economic value to health systems and payers.
Transparent research methodology detailing primary clinical engagement and secondary technical synthesis to ensure validated and actionable insights for stakeholders
The research that underpins these insights relied on a structured methodology combining primary stakeholder engagement and secondary technical synthesis. Primary inputs were gathered through interviews with practicing endoscopists, surgical gastroenterologists, procurement leaders, and distribution partners to capture firsthand perspectives on device usability, training requirements, and purchasing considerations. These qualitative discussions were designed to surface nuanced operational realities that influence adoption in ambulatory surgical centers, academic hospitals, and community hospitals.
Secondary analysis incorporated peer-reviewed clinical literature, regulatory filings, procedure coding guidance, and publicly available technical specifications to validate device capabilities and clinical applicability. Cross-validation of findings ensured that procedural applications, technology distinctions between automated and manual systems, and distinctions between disposable systems and reusable systems were accurately represented. Wherever possible, triangulation between clinician input, published clinical evidence, and device documentation was used to strengthen the reliability of conclusions and recommendations.
Concluding perspective that synthesizes clinical promise, commercial imperatives, and strategic prerequisites for sustainable adoption of endoluminal suturing technologies
In conclusion, endoluminal suturing devices occupy a strategic intersection of clinical innovation and health system optimization. Technological refinements and expanding procedural applications are creating opportunities to shift certain interventions from the operating room to lower-acuity settings, but successful adoption requires more than a capable device. It demands credible evidence, targeted training programs, aligned reimbursement strategies, and resilient supply chain models that together reduce adoption friction and sustain long-term clinical value.
Stakeholders who adopt a segmented approach to product development and commercialization - one that acknowledges differences across product type, technology, application, end user, and distribution channel - will be better positioned to convert clinical potential into routine practice. Regional nuances further underscore the importance of locally tailored strategies. Ultimately, the path to widespread adoption is iterative: continuous clinical engagement, data-driven refinement, and strategic partnerships will determine which solutions deliver scalable benefits to patients and healthcare systems alike.
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
194 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Integration of real-time imaging guidance systems with endoluminal suturing devices for enhanced procedural accuracy
- 5.2. Development of bioresorbable suture anchors to minimize foreign body reaction in gastrointestinal repair applications
- 5.3. Adoption of robotic-assisted endoluminal suturing platforms to improve dexterity in complex intraluminal surgeries
- 5.4. Advancement in AI-driven tissue recognition algorithms for automated suture placement in endoscopic procedures
- 5.5. Emergence of disposable single-use endoluminal suturing tools to reduce cross contamination and streamline workflows
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Endoluminal Suturing Devices Market, by Product Type
- 8.1. Disposable Systems
- 8.2. Reusable Systems
- 9. Endoluminal Suturing Devices Market, by Technology
- 9.1. Automated
- 9.2. Manual
- 10. Endoluminal Suturing Devices Market, by Application
- 10.1. Endoscopic Mucosal Resection
- 10.2. Endoscopic Sleeve Gastroplasty
- 10.3. Endoscopic Submucosal Dissection
- 10.4. Peroral Endoscopic Myotomy
- 11. Endoluminal Suturing Devices Market, by End User
- 11.1. Ambulatory Surgical Centers
- 11.2. Hospitals
- 11.2.1. Academic Hospitals
- 11.2.2. Community Hospitals
- 11.3. Specialty Clinics
- 12. Endoluminal Suturing Devices Market, by Distribution Channel
- 12.1. Direct Sales
- 12.2. Distributors
- 12.2.1. Value Added Resellers
- 12.2.2. Wholesalers
- 13. Endoluminal Suturing Devices Market, by Region
- 13.1. Americas
- 13.1.1. North America
- 13.1.2. Latin America
- 13.2. Europe, Middle East & Africa
- 13.2.1. Europe
- 13.2.2. Middle East
- 13.2.3. Africa
- 13.3. Asia-Pacific
- 14. Endoluminal Suturing Devices Market, by Group
- 14.1. ASEAN
- 14.2. GCC
- 14.3. European Union
- 14.4. BRICS
- 14.5. G7
- 14.6. NATO
- 15. Endoluminal Suturing Devices Market, by Country
- 15.1. United States
- 15.2. Canada
- 15.3. Mexico
- 15.4. Brazil
- 15.5. United Kingdom
- 15.6. Germany
- 15.7. France
- 15.8. Russia
- 15.9. Italy
- 15.10. Spain
- 15.11. China
- 15.12. India
- 15.13. Japan
- 15.14. Australia
- 15.15. South Korea
- 16. Competitive Landscape
- 16.1. Market Share Analysis, 2024
- 16.2. FPNV Positioning Matrix, 2024
- 16.3. Competitive Analysis
- 16.3.1. Apollo Endosurgery, Inc.
- 16.3.2. Aponos Medical LLC
- 16.3.3. Becton, Dickinson company
- 16.3.4. Boston Scientific Corporation
- 16.3.5. Catholic Health Initiatives
- 16.3.6. Cook Medical LLC
- 16.3.7. EndoTools Therapeutics S.A.
- 16.3.8. Fujifilm Holdings Corporation
- 16.3.9. HOYA Corporation
- 16.3.10. Johnson & Johnson
- 16.3.11. KARL STORZ SE & Co. KG
- 16.3.12. Medtronic plc
- 16.3.13. Olympus Corporation
- 16.3.14. Ovesco Endoscopy AG
- 16.3.15. STERIS plc
- 16.3.16. Stryker Corporation
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
